TORONTO and HOUSTON – Medicenna Therapeutics Corp., a company specializing in immunotherapy through the development of Superkines, announced the results of its annual shareholder meeting held today, September 25, 2025. The announcement, made via a press release, highlights the outcomes of key votes taken during the meeting.

Shareholders gathered to cast their votes on a number of important resolutions that will shape the future direction of the company. While the specific details of all resolutions were not immediately available, Medicenna confirmed that all nominated individuals were successfully elected to the board of directors. This indicates a vote of confidence from shareholders in the current leadership and their vision for the company's growth.

The annual meeting serves as a crucial platform for Medicenna to engage with its shareholders, providing an opportunity to discuss the company's performance, strategic initiatives, and future prospects. It also allows shareholders to voice their opinions and participate in key decisions that impact the company's governance.

Medicenna's focus on Superkines positions them at the forefront of innovative cancer treatment. These engineered cytokines, designed to enhance the body's immune response to fight cancer cells, represent a promising new approach to immunotherapy. The company's clinical-stage development programs are closely watched by investors and the medical community alike.

The successful election of all nominees to the board suggests that shareholders are aligned with Medicenna's current strategy and optimistic about the potential of Superkines to revolutionize cancer treatment. Further details regarding the specific voting outcomes and the future plans discussed at the meeting are expected to be released by the company in the coming days. Investors and interested parties are encouraged to monitor Medicenna's official website and regulatory filings for more comprehensive information.